Company to Present Expanded Offerings, Speak on Multiple Panels
Princeton, NJ – June 21, 2012 – PharmaNet/i3, inVentiv Health’s clinical segment, and a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, today announced it will participate at DIA 2012 in Philadelphia from June 24-28, 2012. Experts from PharmaNet/i3 will address some of the latest drug development outsourcing trends during several DIA program sessions.
“At DIA 2012, we are excited to showcase our expanded global offerings that reinforce our ability to deliver tailored solutions that help sponsors achieve their clinical and financial objectives,” said Jeffrey P. McMullen, President and CEO, PharmaNet/i3.
PharmaNet/i3 can be found at Booth 2213 in the exhibitor hall and will tweet live meeting highlights from Twitter handle @PharmaNet_i3. Highlights of PharmaNet/i3 DIA program sessions and in-booth speakers include:
Tuesday, June 26
1:30 p.m. Track 03 - Innovative Partnering Models and Outsourcing Strategies: “Collaborative Partnerships in Drug Development: An Executive Roundtable,” Jeffrey P. McMullen, President and CEO, along other executives form the CRO industry.
1:30 p.m. Track 01 - Clinical Operations: “Investigator Budgets’ Impact on Patient Enrollment and Retention: How to Improve Sponsor/CRO/Site Selection Processes,” Kellie Malloy, Vice President and General Manager, Pain Management and Inflammatory, Cardiovascular and Metabolic Disease
Wednesday, June 27
3:30 p.m. Track 01 - Clinical Operations: “Optimizing Study Monitoring Performance and Efficiency,” Lisa Rhiner, Clinical Study Lead
Monday, June 25
11:45 a.m. “How Strategic Resourcing Can Lower Your Costs,” Brian Thornton, Senior Vice President, Strategic Resourcing
1 p.m. “How to Get the Most Out of Your Clinical FSP,” Eleanore Doyle, Vice President, Strategic Resourcing
3 p.m. “Global Staffing Solutions with a Local Flavor,” Mary Painter, Senior Account Manager, Global Staffing
5:30 p.m. DIA Opening Reception at PharmaNet/i3 Booth 2213, Welcome remarks from Gregg Dearhammer, President, PharmaNet/i3 Strategic Resourcing
Tuesday, June 26
9:45 a.m. “Observational Research: Areas of Consensus and Divergence,” Jeff Trotter, Executive Vice President, Phase IV Development
11:45 a.m. “Enhancing Quality in Your Strategic Partnership,” Randy Kehrmeyer, Vice President, Strategic Resourcing
1 p.m. “Global Clinical Trial Patient Recruitment: One Size Does NOT Fit Most,” Julie Ross, Senior Vice President, Global Strategic Services
3 p.m. “How to Get the Most Out of Your Clinical FSP,” Eleanore Doyle, Vice President, Strategic Resourcing
Wednesday, June 27
9:45 a.m. “How Strategic Resourcing Can Lower Your Costs,” Brian Thornton, Senior Vice President, Strategic Resourcing
PharmaNet/i3, the inVentiv Health clinical segment, is recognized as a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, including therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and staffing from a single clinical professional to an entire functional team. For intelligent solutions needed to accelerate high quality drug development programs of all sizes around the world, PharmaNet/i3 works for you. For more information, visit www.pharmanet-i3.com.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced acquisitions, and any additional leverage we may incur in connection with the financing thereof, on the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our credit facility and to access sufficient capital to fund our operations; the impact of any default by any of our credit providers or swap counterparties; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability accurately forecast insurance claims within our self-insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses, including the acquisitions of i3 Global and PharmaNet Development Group, Inc., into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; and the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Readers of this press release are referred to documents which may be filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
Contact: Anne-Marie Hess, Vice President, Marketing & Communications
Phone: +1 609 951 6842
# # #